Health TrialsbyHealthPanel

Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases

ConditionsTumorCardiovascular DiseasesPulmonary FibrosisRheumatic Immune Diseases Involving Large Blood VesselsHypertrophic Cardiomyopathy (HCM)Other Hypoxic and Fibroblast Activated Diseases
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-85
SponsorPeking Union Medical College Hospital

About this trial

The purpose of this study is to conduct clinical research on \[68Ga\] Ga-NI-FAPI-04 PET/CT imaging and further investigate its diagnostic value in fibroblast activation related diseases.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

1: 18-85 years old

Disqualifiers

1: Pregnant or lactating women

Trial design

Design model

Single group

Treatments tested in this trial

  • Injection of 68Ga-NI-FAPI

    Drug

    Subjects were injected with 68Ga-NI-FAPI at 0.4-0.5mci/kg body weight

Treatment groups

30 Participants
are divided into 1 treatment group
Group A: NI-FAPI groupExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Analysis of PET/CT Images of [68Ga] Ga-NI-FAPI-04

Semi quantitative analysis (measuring lesion standard uptake value (SUV), then calculating lesion SUV to liver/blood pool SUV ratio)

Time frame
Within 30-120 minutes after intravenous injection of imaging agent

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Peking Union Medical College Hospital

Lead sponsor

Source ClinicalTrials.gov
Apply now